"Biological Products" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay.
Descriptor ID |
D001688
|
MeSH Number(s) |
D20.215
|
Concept/Terms |
Biological Products- Biological Products
- Biologic Products
- Products, Biologic
- Biologics
- Products, Biological
|
Below are MeSH descriptors whose meaning is more general than "Biological Products".
Below are MeSH descriptors whose meaning is more specific than "Biological Products".
This graph shows the total number of publications written about "Biological Products" by people in this website by year, and whether "Biological Products" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2006 | 1 | 0 | 1 |
2008 | 2 | 1 | 3 |
2009 | 1 | 0 | 1 |
2010 | 1 | 2 | 3 |
2011 | 2 | 0 | 2 |
2012 | 3 | 0 | 3 |
2013 | 4 | 1 | 5 |
2015 | 3 | 0 | 3 |
2016 | 4 | 2 | 6 |
2017 | 3 | 0 | 3 |
2018 | 3 | 0 | 3 |
2019 | 3 | 1 | 4 |
2020 | 4 | 1 | 5 |
2021 | 2 | 0 | 2 |
2022 | 9 | 0 | 9 |
2023 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biological Products" by people in Profiles.
-
Bessette L, Movahedi M, Reed G, Kremer JM, Kane K, Keystone E. Does the Type of Failure and the Choice of the Second Biologic Influence Response and Persistence on Medication in Rheumatoid Arthritis? J Clin Rheumatol. 2023 Oct 01; 29(7):332-340.
-
Sparks JA, Harrold LR, Simon TA, Wittstock K, Kelly S, Lozenski K, Khaychuk V, Michaud K. Comparative effectiveness of treatments for rheumatoid arthritis in clinical practice: A systematic review. Semin Arthritis Rheum. 2023 10; 62:152249.
-
Vu M, Ghosh S, Umashankar K, Weber L, Landis C, Candela N, Chastek B. Comparison of surgery rates in biologic-na?ve patients with Crohn's disease treated with vedolizumab or ustekinumab: findings from SOJOURN. BMC Gastroenterol. 2023 Mar 25; 23(1):87.
-
Kaplan JL, Liu C, King EC, Bass JA, Patel AS, Tung J, Chen S, Lissoos T, Candela N, Saeed S, Colletti RB. Use, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric-Onset IBD Cohort. J Pediatr Gastroenterol Nutr. 2023 05 01; 76(5):566-575.
-
Akenroye A, Zhou G, Jackson JW, Segal J, Alexander GC, Singh S. Incidence of adverse events prompting switching between biologics among adults with asthma: A retrospective cohort study. Allergy. 2023 04; 78(4):1116-1119.
-
Ungaro RC, Chou B, Mo J, Ursos L, Twardowski R, Candela N, Colombel JF. Impact of COVID-19 on Healthcare Resource Utilisation Among Patients with Inflammatory Bowel Disease in the USA. J Crohns Colitis. 2022 Sep 08; 16(9):1405-1414.
-
Chari DA, Madhani A, Sharon JD, Lewis RF. Evidence for cognitive impairment in patients with vestibular disorders. J Neurol. 2022 Nov; 269(11):5831-5842.
-
Baker JF, Reed G, Poudel DR, Harrold LR, Kremer JM. Obesity and Response to Advanced Therapies in Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2022 11; 74(11):1909-1916.
-
Hsueh YC, Wang Y, Riding RL, Catalano DE, Lu YJ, Richmond JM, Siegel DL, Rusckowski M, Stanley JR, Harris JE. A Keratinocyte-Tethered Biologic Enables Location-Precise Treatment in Mouse Vitiligo. J Invest Dermatol. 2022 Dec; 142(12):3294-3303.
-
Patel D, Svoboda R, Maczuga S, Foulke GT, Helm M. A retrospective claims analysis confirms the cost of most biologic agents for psoriasis is increasing more rapidly than medical inflation. J Am Acad Dermatol. 2023 02; 88(2):490-493.